BIOQUAL Inc. reports recurring financial results and governance updates as an OTC Pink/Pink Limited public company. Its announcements center on quarterly and annual revenue, income or loss before taxes, net income or loss, earnings per common share, and weighted average shares outstanding.
Company news also documents board and senior leadership changes, including retirements and appointments connected to corporate oversight and BIOQUAL's contract research program.
BIOQUAL, Inc. (OTC-PINK:BIOQ) reported its financial results for the three months ended August 31, 2021. The company achieved revenue of $15,472,759, a rise from $14,920,475 in the same period of 2020. Despite the increase in revenue, net income declined to $1,377,005 compared to $1,766,588 in the prior year. The basic earnings per share decreased to $1.54 from $1.98. The company emphasizes ongoing risks and uncertainties that could impact future performance.
BIOQUAL, Inc. (OTC-Pink:BIOQ) reported significant financial growth for the fiscal year 2021, with revenues reaching $57.68 million, up from $46.36 million in 2020. The net income also saw an increase to $6.33 million compared to $4.23 million the previous year. The company declared a $1.25 per share dividend for shareholders of record as of September 29, 2021, payable on October 20, 2021. This marks the twentieth dividend declaration by BIOQUAL, reflecting its commitment to returning value to shareholders.
BIOQUAL, Inc. (OTC-Pink:BIOQ) reported strong financial results for the nine months ended February 28, 2021, with revenues reaching $41,070,486, up from $32,884,055 in the prior year. Net income rose to $4,203,962, compared to $2,936,730 last year. Basic and diluted earnings per share increased significantly to $4.70 and $4.70, respectively. For the third quarter alone, revenues were $12,584,303, higher than $11,593,217 in the same quarter of the previous year. This reflects strong year-over-year growth and improved profitability.
Dr. John C. Landon, former president, CEO, and chairman of the board of BIOQUAL, passed away on January 10, 2021, at age 84. A distinguished biologist, he contributed significantly to cancer research and led BIOQUAL from a small enterprise to a $20 million life sciences corporation. Under his leadership, BIOQUAL expanded its services to include pivotal roles in vaccine and therapeutic research, notably in combating COVID-19. His legacy is marked by advancements in biomedical research and his dedication to enhancing global health.
BIOQUAL, Inc. (OTC Pink: BIOQ) reported its unaudited second quarter results for fiscal year 2021. Revenue increased to $28,486,183 for the six months ended November 30, 2020, compared to $21,290,838 for the same period in 2019. Net income also rose to $3,228,002, up from $2,216,324 year-over-year. The company reported basic earnings per share of $3.61 for the period, reflecting a solid financial performance despite ongoing risks related to government contracts and reliance on third-party services.